Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy (2015)
- Authors:
- Autor USP: HOFF, PAULO MARCELO GEHM - FM
- Unidade: FM
- DOI: 10.1016/j.ejca.2014.10.019
- Subjects: NEOPLASIAS COLORRETAIS (TERAPIA); FATORES DE CRESCIMENTO; QUIMIOTERAPIA
- Language: Inglês
- Imprenta:
- Source:
- Título: European Journal of Cancer
- ISSN: 0959-8049
- Volume/Número/Paginação/Ano: v. 51, n. 1, p. 18-26, 2015
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
RUFF, Paul et al. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. European Journal of Cancer, v. 51, n. 1, p. 18-26, 2015Tradução . . Disponível em: https://doi.org/10.1016/j.ejca.2014.10.019. Acesso em: 04 mar. 2026. -
APA
Ruff, P., Ferry, D. R., Lakomỳ, R., McWalter, G., Van Hazel, G. A., Hoff, P. M., et al. (2015). Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. European Journal of Cancer, 51( 1), 18-26. doi:10.1016/j.ejca.2014.10.019 -
NLM
Ruff P, Ferry DR, Lakomỳ R, McWalter G, Van Hazel GA, Hoff PM, Cunningham D, Arnold D, Schmoll HJ, Moiseyenko VM, McKendrick JJ, ten Tije AJ, Vishwanath RL, Bhargava P, Chevalier S, Macarulla T, Cutsem EV. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy [Internet]. European Journal of Cancer. 2015 ; 51( 1): 18-26.[citado 2026 mar. 04 ] Available from: https://doi.org/10.1016/j.ejca.2014.10.019 -
Vancouver
Ruff P, Ferry DR, Lakomỳ R, McWalter G, Van Hazel GA, Hoff PM, Cunningham D, Arnold D, Schmoll HJ, Moiseyenko VM, McKendrick JJ, ten Tije AJ, Vishwanath RL, Bhargava P, Chevalier S, Macarulla T, Cutsem EV. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy [Internet]. European Journal of Cancer. 2015 ; 51( 1): 18-26.[citado 2026 mar. 04 ] Available from: https://doi.org/10.1016/j.ejca.2014.10.019 - Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy?
- Primary prevention of colorectal cancer: Myth or reality?
- Drogas moleculares
- Perspectivas no cuidado dos tumores gastrointestinais
- Obesidade e câncer
- Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors
- Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer
- Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group
- Lack of association between ERCC1 expression in biliary tract malignancy and response to chemotherapy
- Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas
Informações sobre o DOI: 10.1016/j.ejca.2014.10.019 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
